| Assessment Status |
Rapid Review Complete |
| HTA ID |
22057 |
| Drug |
Lenvatinib |
| Brand |
Kisplyx® |
| Indication |
For the treatment of adults with advanced renal cell carcinoma, in combination with pembrolizumab, as first-line treatment |
| Rapid review commissioned |
15/08/2022 |
| Rapid review completed |
22/09/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib in combination with pembrolizumab for first-line treatment of patients with advanced RCC compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
